XLRN News and Press, Acceleron Pharma Inc. From 05/08/21

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Acceleron Pharma Inc. 2021 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Acceleron Pharma Inc (NASDAQ: XLRN) Q1 2021 Earnings Call May 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Acceleron Pharma Inc (XLRN) Q1 2021 Earnings Call Transcript

Acceleron Pharma (XLRN): Q1 Non-GAAP EPS of -$0.77 beats by $0.07; GAAP EPS of -$1.05 misses by $0.24.Revenue of $24.76M (+470.5% Y/Y) misses by $4.02M.Press Release For further details see: Acceleron Pharma EPS beats by $0.07, misses on revenue

- PULSAR Phase 2 trial results published in New England Journal of Medicine - - Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society (ATS) 2021 International Co...

Acceleron Pharma (NASDAQ:XLRN) is scheduled to announce Q1 earnings results on Thursday, May 6th, after market close.The consensus EPS Estimate is -$0.84 (+11.6% Y/Y) and the consensus Revenue Estimate is $28.78M (+563.1% Y/Y).Over the last 2 years, XLRN has beaten EPS estimates 50% of the ti...

- Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical com...

The FDA has issued a notice of noncompliance to Acceleron Pharma (XLRN) for failing to submit data from a phase 2 trial of an oncologic to the clinicaltrials.gov database as required.The trial involved explored a combination of dalantercept and axitinib compared to axitinib and placebo alone ...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Medi...

Acceleron’s stock price is near a 52-week high. Reblozyl sales are growing rapidly. While a favorite biotech for the long term, Acceleron is currently fairly priced. For further details see: Acceleron: Neutral On Stock Price Gains

– Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patients – – Interim results from the SPECTRA Phase 2 trial to show i...